
Axon Neuroscience is a clinical-stage biotechnology leader pioneering tau-targeted therapies to prevent and treat Alzheimer’s disease and related neurodegenerative disorders. Founded in by Prof. Michal Novak, who discovered the tau protein as a key cause of Alzheimer’s disease, Axon has built the world’s largest dedicated tau research team with over 20 senior in-house scientists advancing cutting-edge programs from discovery to clinical development. Axon’s lead candidate, AADvac1, is the most clinically advanced active vaccine targeting pathological tau. In the successful Phase II ADAMANT…
Built from contact records that share this company: name, job title, job level, job function and person location.
Turn cold outreach into meaningful business conversations.
Rated and recommended by professionals who expect more
Annual Revenue$10M to $25M
Estimated OwnershipPrivate